Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?

This publication has 27 references indexed in Scilit:

• A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais
  Vaccine, 2000
• Vaccination of Seronegative Volunteers with a Human Immunodeficiency Virus Type 1env/revDNA Vaccine Induces Antigen‐Specific Proliferation and Lymphocyte Production of β‐Chemokines
  The Journal of Infectious Diseases, 2000
• Development of Bivalent (B/E) Vaccines Able to Neutralize CCR5-Dependent Viruses from the United States and Thailand
  Virology, 1999
• New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview
  Comptes Rendus de l'Académie des Sciences - Series III - Sciences de la Vie, 1999
• HIV-1 DNA vaccines and chemokines
  Vaccine, 1999
• A Canarypox Vaccine Expressing Multiple Human Immunodeficiency Virus Type 1 Genes Given Alone or with Rgp120 Elicits Broad and Durable CD8⁺Cytotoxic T Lymphocyte Responses in Seronegative Volunteers
  The Journal of Infectious Diseases, 1999
• Willingness of Injection Drug Users to Participate in an HIV Vaccine Efficacy Trial in Bangkok, Thailand
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
• Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy
  Statistics in Medicine, 1998
• Intermediate-Size Trials for the Evaluation of HIV Vaccine Candidates: A Workshop Summary
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 1997
• HIV vaccine development
  AIDS, 1996